Page 184 - SAMRC Annual Report 2023-24

Strategic Significant risk Risk Key response
priorities category/context description measures
Lead the Health, Safety & HSE exposures on premises • Dedicated HSE team
generation of Environment (HSE) and community-based • HSE Management System
new knowledge research programmes, delays • Emergency Preparedness and
programmes/project and adverse Response Procedure
impact on future funding

Maintaining research The risk involves application of • Establish Research
integrity inconsistent data management Integrity Office
processes; inadequate structured • Human and animal
mentorship and onerous new ethics committees
legislative requirements imposed • Policies, guidelines and SOPs

Transformation Progression of staff • EE Strategy & Plan
transformation across the • Strengthened Transformation
organisation at senior research forum with inclusion of the
level impacted by various EE and Skills development
factors, including due to lack of Committee
staff turnover, limited budget • Appointed designated
and scarce skills shortage in Transformation Executive
medical science and Office
• Diversity intervention initiatives
and leadership programs
Leadership Sustained leadership at • Development of defined
EMC level strategies and continually
enhancing to strengthen
sustained leadership

Refocus of the Focusing on current and new • Realigned research focus in
Intra-Mural domain emerging/re-emerging epidemics place
and pandemics. Effect of climate
change on health and increased
prevalence of NCDs

Funding Inability to maintain and • Dedicated ongoing
appropriately diversify incoming investigation for further local
funding to generate future and international funding
funding opportunities opportunities in both the
private and public sector
Support, through Lack of further Limited funding for/value • IP and Commercialization
funding and other development and proposition of the innovation Policy, Strategy and Procedures
mechanisms, commercialization of reducing interest from industry to • External partnering to
technology (a) SAMRC-owned and commercialize or target market to pursue commercialisation
development and (b) SAMRC-funded implement the innovation opportunities
implementation, innovations
and innovations
in health and
technology delivery
to improve health

182 SAMRC ANNUAL REPOR T 2023-24